Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”).
Throughout the Class Period, on earnings and shareholder calls, Defendants continually praised their alleged growth, foreseeing record numbers of new patients and outpacing their prior fiscal year’s gross margins, while continually minimizing the risks associated with scaling their customer transition to the G7 platform, as well as those associated with seasonality and the potential impact of the macroeconomic environment on the company’s profitability.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DexCom’s communications about growth and anticipated margins were unreasonably optimistic due to its reliance on attracting new customers; (2) DexCom was struggling to keep existing distribution channels successful; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On October 7, 2025, Defendants filed an Answer to the Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.